CPC Scientific

What CPC Scientific does

CPC Scientific is a Contract Research, Development, and Manufacturing Organization (CRDMO) founded in 2001 and headquartered in Rocklin, California, with primary GMP manufacturing operations in Hangzhou, China, through its Chinese Peptide Company subsidiary. The company is a wholly owned subsidiary of Hong Kong-listed Medtide Inc. (HKEX: 03880), which completed its IPO in June 2025. CPC Scientific specializes in synthetic peptide and oligonucleotide production, with core technical capabilities spanning Solid-Phase Peptide Synthesis (Fmoc, Boc, Cbz), Liquid-Phase Synthesis, ligation chemistry, and peptide-oligonucleotide conjugates including POCs, PDCs, and RDCs. It maintains 26,000 sqm of GMP manufacturing infrastructure with 19 synthesis suites, 16 purification suites, reactor volumes up to 1,000L, and an annual API capacity exceeding 1,000 kg at 20-25 kg per batch.

The company's product and service portfolio spans the full peptide lifecycle: custom research-grade peptide synthesis, a 1,200+ sequence catalog across 21 research areas, FTE-based discovery services, GMP peptide manufacturing for Phase I through commercial supply, GMP oligonucleotide manufacturing (1-17 kg annual capacity), generic peptide API development (Leuprorelin, Triptorelin, Cetrorelix, Goserelin, Teduglutide), cosmetic peptides, neoantigen peptides, and a broad peptide modifications portfolio (macrocycles, stapled peptides, PEGylated, dye-labeled, glycosylated, click, peptoids, long sequences, D-amino acids, isotope-labeled). Regulatory credentials include FDA DMFs for Tirzepatide (DMF 043979, May 2026) and Cetrorelix (DMF 034884), five successful FDA inspections, and certifications from EMA, TGA, MFDS, NMPA, and three ISO standards.

CPC Scientific operates an enterprise field-sales model supplemented by industry conference presence (CPHI Frankfurt/Korea/Milan, TIDES Europe, BioJapan, DCAT), direct quotation-based GMP sales, an e-commerce catalog for research peptides, and FedEx international shipping across 50+ countries. Customer segments span pharmaceutical companies, biotechnology companies, academic and research institutions, cosmetics companies, and generic drug manufacturers, with 300+ ongoing CMC development projects and 13 commercial GMP programs as of 2025. Revenue is generated through one-time custom and catalog purchases, multi-year managed GMP manufacturing contracts, FTE-based professional services, and commercial API licensing, though specific revenue figures are not publicly disclosed.

Name

CPC Scientific

Legal name

CPC Scientific Inc.

Website

https://cpcscientific.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

501–1,000 employees

Short description

CPC Scientific is a CRDMO specializing in synthetic peptides and oligonucleotides, serving pharmaceutical, biotechnology, academic, cosmetic, and generic drug manufacturers globally through custom research, GMP manufacturing, and commercial API production across 50+ countries.

Ownership category

akta.pro rank

Product category

Contract Peptide and Oligonucleotide Manufacturing (CRDMO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industries

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

Keywords

• Peptide CDMO services
• Oligonucleotide manufacturing
• GMP peptide API
• Custom peptide synthesis
• Peptide oligonucleotide conjugates

Headquarters

HQ city

Rocklin

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Custom Peptide Synthesis Services: CRO services including peptide NCE discovery synthesis and custom peptide manufacturing for research purposes
2. GMP Peptide Manufacturing (CDMO): Contract development and manufacturing services for peptide CMC development, late-phase development, and commercial production under GMP conditions
3. Commercial API Manufacturing (CMO): Contract manufacturing for peptide NCE and generic drug commercial production, including regulatory filing support (DMF preparation)
4. Catalog Peptide Sales: Sale of pre-made catalog peptides (1,200+ sequences across 21 research areas) with pricing from $16.50 to $1,386+ per unit
5. FTE (Full-Time Equivalent) Services: Discovery chemistry services providing dedicated scientific staff allocation for flexible, continuous project support
6. Generic Peptide APIs: Commercial generic peptide API manufacturing for approved indications including cancer, diabetes, obesity, and multiple sclerosis treatments

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

CPC Scientific is a Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end synthetic peptide and oligonucleotide services to pharmaceutical and biotechnology companies. Its core offerings span custom research peptide synthesis and catalog peptide sales, peptide modifications (macrocycles, stapled peptides, PEGylation, glycosylation, etc.), Phase I–III and commercial GMP peptide manufacturing, generic peptide API production, GMP oligonucleotide manufacturing, and integrated peptide-oligonucleotide conjugates (POC/PDC/RDC).

Product overview

CPC Scientific is a Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in synthetic peptides and oligonucleotides. The company operates as a single integrated platform offering end-to-end services from discovery through commercial manufacturing. The core product portfolio centers on GMP Peptide Manufacturing (including Phase I-III and commercial GMP programs), Research Peptides (custom synthesis and catalog offerings with 1,200+ sequences), and GMP Oligonucleotide Manufacturing. These are supplemented by Peptide-Oligonucleotide Conjugates, Generic Peptides API Development, Cosmetic Peptides, Neoantigen Peptides, FTE Services, and a comprehensive Peptide Modifications Portfolio covering macrocycles, stapled peptides, PEGylation, dye-labeling, and other specialized modifications. The platform is vertically integrated to support pharmaceutical and biotech partners across the entire therapeutic lifecycle.

Differentiator

Problem solved

Functional benefit

Products and services

• GMP Peptide Manufacturing Large-scale, late-phase, and commercial GMP peptide manufacturing services with annual API production capacity over 1,000 kg and per-batch capacity of 20–25 kg. Supports projects from early discovery through commercialization with CGMP compliance for NMPA, FDA, EMA, TGA, and MFDS regulatory authorities. For pharmaceutical and biotechnology clients.
• Custom Peptide Synthesis (Research Peptides) Custom peptide synthesis services providing reliable, high-quality peptides directly to researchers and institutions, including complex modifications (macrocycles, stapled peptides, dye-labeled, PEGylated, click, glycosylated, phosphorylated, peptoids, unnatural amino acids, peptide libraries, lipopeptides, multiple disulfide bridges, long sequences, D-amino acids, isotope labeled). Includes a 1,200+ catalog of pre-made peptides across 21 research areas.
• GMP Oligonucleotide Manufacturing Research-grade and clinical-grade oligonucleotide manufacturing services spanning from discovery to clinical phases, with recently reconfigured capacity for 1–17 kilograms of oligonucleotides annually.
• Peptide-Oligonucleotide Conjugates Seamlessly integrates peptide and oligonucleotide platforms to produce peptide conjugates including peptide-oligonucleotide conjugates (POC), peptide drug conjugates (PDC), and radionuclide drug conjugates (RDC).
• Generic Peptide API Development Commercial generic API manufacturing including Leuprorelin Acetate, Triptorelin Acetate, Cetrorelix Acetate, Goserelin Acetate, Triptorelin Pamoate, and Teduglutide for treatment of cancer, diabetes, obesity, and multiple sclerosis.
• Cosmetic Peptides Cosmetic peptide ingredient synthesis for anti-aging, wound healing, and skin care applications. Manufacturing capacity ranges from mg quantities through 100 kg commercialization scale, with ISO 22716 GMP compliance.
• Neoantigen Peptides Custom neoantigen peptide synthesis services for personalized therapeutic applications.
• FTE Services Full-time equivalent (FTE) based discovery chemistry services for synthetic peptides, providing dedicated scientific support with flexible resource allocation and continuous project engagement.

Quantifiable outcome

• 300+ ongoing CMC development projects supported
• +4 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators12 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• CordenPharma: Global CDMO with a dedicated peptide platform offering custom synthesis, GMP manufacturing, and generic peptide APIs across multiple sites—competes head-to-head with CPC for both commercial peptide API and complex modification projects.
• WuXi STA (WuXi AppTec): China-based CRDMO with a major peptide and oligonucleotide franchise plus much broader small molecule and biologic capabilities—directly comparable to CPC's peptide CRDMO model while also competing on geographic flexibility and scale.
• PolyPeptide Group: Public peptide CDMO offering custom and GMP-grade peptides for pharma and biotech, with comparable end-to-end capabilities across APIs, generic peptides, and complex modifications—directly competes with CPC for the same customer profile.
• Senn Chemicals: Swiss peptide CDMO offering custom peptide synthesis, GMP production, and a generic peptide API portfolio—directly comparable to CPC's discovery-through-commercial peptide services for pharma and biotech customers.
• Bachem: Swiss-headquartered global leader in peptide and oligonucleotide CDMO services with large-scale GMP manufacturing, extensive DMF portfolio, and a similar end-to-end offering from custom synthesis through commercial API production—CPC's most direct competitor in peptide API.
• Avecia (Nitto Denko Avecia): Specialist oligonucleotide CDMO offering custom and GMP oligo manufacturing—directly comparable to CPC's recently expanded GMP oligonucleotide platform and peptide-oligonucleotide conjugate capability.
• AmbioPharm: US- and China-based peptide CDMO specializing in custom peptide synthesis, GMP manufacturing, and generic peptide APIs—closely comparable to CPC across both research and commercial peptide manufacturing.

Broad incumbents

• Lonza: Largest global CDMO with a peptide and small-molecule API platform alongside biologics, cell & gene, and other modalities—overlaps with CPC on peptide CMC and commercial API but operates at far greater scale and modality breadth.

Emerging players

• Syngene International: India-based integrated CRDMO with peptide, small molecule, and biologics capabilities—competes with CPC for biotech CDMO contracts, particularly for customers seeking alternative geographic supply outside US/EU/China.
• GenScript ProBio: CDMO arm of GenScript offering peptide synthesis, biologics, plasmid, and cell therapy services with growing GMP capacity—an emerging player whose peptide services increasingly compete with CPC for biotech customers in Asia and globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CPC_Scientific
• Facebookfacebook.com/CPC-Scientific-Inc-110740840715572

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CPC Scientific